Compare MCI & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCI | OVID |
|---|---|---|
| Founded | 1971 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.0M | 365.5M |
| IPO Year | N/A | 2017 |
| Metric | MCI | OVID |
|---|---|---|
| Price | $17.55 | $2.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.60 |
| AVG Volume (30 Days) | 45.5K | ★ 3.0M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 8.46% | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.34 |
| P/E Ratio | $9.64 | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $17.24 | $0.27 |
| 52 Week High | $23.00 | $3.11 |
| Indicator | MCI | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 40.88 | 60.07 |
| Support Level | $17.27 | $2.56 |
| Resistance Level | $18.19 | $3.11 |
| Average True Range (ATR) | 0.34 | 0.15 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 41.30 | 55.68 |
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.